Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt. - Investment expected to generate more than 160 new jobs and supports company's ongoing growth in core product technology-
ST. ALBANS, Vt., Sept. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the completion of an 85,000 square foot, three-story expansion project at its transdermal patch facility, operated by Mylan Technologies Inc. (MTI), in St. Albans, Vt. Through Mylan's investment, including funding for expanded research and development (R&D) capabilities and additional manufacturing and laboratory space, the company is in the process of adding more than 160 new positions to its St. Albans-based workforce. MTI is a proven leader in transdermal drug delivery systems – patches that deliver medication through the skin – and related technologies.
In conjunction with the expansion project, Mylan today hosted a ribbon-cutting ceremony to commemorate the occasion. Vermont Governor Peter Shumlin as well as a number of local officials, community members and employees, attended the event.
Mylan CEO Heather Bresch said: "Mylan's investment in the ongoing growth of our transdermal franchise demonstrates our continued commitment to and confidence in our ability to provide complex generic and interchangeable products and innovative delivery alternatives, such as transdermals. Through this expansion, MTI will continue to play a critical role in the expansion and diversification of Mylan's global product portfolio, especially when it comes to difficult-to-develop and –manufacture products. I would like to thank Governor Shumlin as well as the city of St. Albans for their ongoing support of this project. Importantly, I would also like to recognize Mylan's more than 590 employees in Vermont for their hard work and dedication to our continued success."
The 14-month expansion project has increased MTI's total operating space to more than 391,000 square feet. Since becoming a part of the Mylan manufacturing network more than 20 years ago, MTI has developed a number of branded and generic transdermal products available to patients in markets around the world, including the U.S., Canada, Europe, Japan, New Zealand and Australia.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.